The pharmaceutical and AI sectors are moving closer together as NVIDIA and Eli Lilly unveil a long term collaboration focused on transforming how new medicines are discovered using artificial intelligence. The collaboration also reflects NVIDIA’s broader push to open and accelerate AI innovation across healthcare and life sciences.
Announced on January 12, 2026, the partnership centers on a dedicated AI co-innovation lab designed to merge advanced computing with real world drug research. Both companies plan to jointly invest up to $1 billion over five years to support infrastructure, talent and large scale computing capacity.
The lab will operate in the San Francisco Bay Area and bring together Lilly scientists with NVIDIA’s AI researchers and engineers. This close collaboration aims to shorten feedback loops between experimental biology and computational modeling.
Key Objectives of The AI Lab Include:
- Accelerating drug discovery using large scale AI models
- Enabling continuous learning from wet lab and digital experiments
- Generating high quality biological and chemical datasets
- Expanding AI use beyond discovery into clinical and manufacturing stages
The initiative builds on Lilly’s earlier investments in AI-driven research infrastructure while leveraging NVIDIA’s latest platforms optimized for life sciences. Together, the companies aim to create a continuously operating discovery system that could redefine speed, scale and accuracy in drug development.
